Key Highlights
- In a June 30, 2026 release, Moleculin reported preliminary unblinded first-cycle data from 45 R/R AML patients in the MIRACLE trial: complete remission (CR) of 43% and 36% in its two Annamycin dose arms versus 12% for the cytarabine-only control, and composite complete remission (CRc) of 50% and 57% versus 29%.
- The trial's independent data monitoring committee found no statistical significance at this first interim look but recommended continuing without dropping either dose arm; Part A enrollment stood at 67 of a planned 90 subjects (about 74%) as of June 30, 2026.
- Moleculin's Form 10-Q for the quarter ended March 31, 2026 disclosed $10.3 million in cash, an accumulated deficit of $218.8 million, and going-concern doubt; the company completed a 1-for-25 reverse split in December 2025 and only regained full Nasdaq compliance in January 2026.
- The timeline calls for completing Part A and unblinding in the third quarter of 2026, starting Part B in the second half of 2026, beginning third-line and pediatric AML studies in 2027, ending Part B recruitment in 2028, and beginning a rolling NDA submission in 2028 targeting accelerated approval on the CR endpoint.
Moleculin Biotech (NASDAQ:MBRX) says preliminary, unblinded data from the first 45 patients in its pivotal MIRACLE trial of Annamycin plus cytarabine in relapsed or refractory AML beat a concurrent control arm on remission rates. An independent monitoring committee recommended the study continue. The signal is early and statistically inconclusive, and arrives as Moleculin manages a thin cash balance, a recent reverse split and a resolved but recent Nasdaq compliance scare.
Why Moleculin Is Back in Investors' Crosshairs
Moleculin Biotech has spent years advancing Annamycin, a reengineered anthracycline designed to sidestep the multidrug-resistance mechanisms and cumulative heart damage that limit older drugs such as doxorubicin. On June 30, 2026, the Houston-based company announced preliminary unblinded results from the first 45 patients in its pivotal Phase 2/3 MIRACLE trial testing Annamycin combined with cytarabine (AnnAraC) in relapsed or refractory acute myeloid leukemia (R/R AML), a population with few effective options. Both Annamycin dose arms outperformed control on complete remission. Management repeated the same numbers in a July 6, 2026 CEO video interview; since both trace to the June 30 disclosure, this article relies on that release and Moleculin's SEC filings.
Inside Moleculin's Annamycin Platform and the MIRACLE Design
Moleculin is a clinical-stage pharmaceutical company with no approved products and no product revenue. Annamycin (also called naxtarubicin) previously completed a Phase 1B/2 study (MB-106) in R/R AML and soft-tissue sarcoma lung metastases before advancing into MIRACLE (MB-108), a pivotal, adaptive-design, randomized, double-blind, placebo-controlled Phase 2/3 trial. MIRACLE compares two Annamycin doses, 190 mg/m² and 230 mg/m², each combined with high-dose cytarabine (HiDAC), against HiDAC plus placebo as second-line induction therapy. Part A is a dose-selection phase targeting 90 subjects; the selected dose then carries into Part B, a pivotal expansion toward roughly 282 total subjects. Moleculin also runs smaller, investigator-funded programs around WP1066 and WP1122, but MIRACLE is the clear value driver.
What the MIRACLE Trial Data in Moleculin Biotech (MBRX) Actually Show
In the 45-patient population, analyzed on a full intent-to-treat basis, CR reached 43% and 36% in the two Annamycin arms versus 12% for control, while CRc reached 50% and 57% versus 29%. These are single-cycle results, as specified by protocol, whereas historical benchmarks Moleculin cites, including MIRROS, CLASSIC I and its own MB-106 trial, permitted multiple cycles, making cross-trial comparison imperfect. The independent Data Monitoring Committee (iDMC) unanimously found no statistical significance, consistent with a prespecified O'Brien-Fleming design that reserves nearly all statistical power for the final analysis.
The iDMC noted a numeric trend favoring both arms and recommended continuing without dropping either dose; Moleculin accepted. This is a small-sample (n=45), unblinded subset that is directionally encouraging but not proof of efficacy: Moleculin's own forward-looking language concedes results "may not be predictive of results from the completed trial." As of June 30, 2026, 67 of 90 targeted subjects had enrolled, with full Part A enrollment and unblinding guided for the third quarter of 2026.
First-Quarter 2026 Results and Trial Operating Costs
For the quarter ended March 31, 2026, R&D expense was $5.4 million, up from $3.4 million a year earlier, mainly on $1.4 million of incremental MIRACLE costs in Europe. G&A expense was roughly flat at $2.5 million. Net loss was $12.8 million versus $5.9 million, skewed by non-cash warrant accounting, including a $10.8 million fair-value gain on warrant liabilities offset by a $15.2 million loss on issuing new warrant liabilities. Net loss per share was $(3.54) on 4.1 million weighted average shares.
Cash Position, Dilution and the Reverse Split Behind the Numbers
As of March 31, 2026, Moleculin held cash of $10.3 million and equity of $15.2 million against an accumulated deficit of $218.8 million. The 10-Q states management does not believe this cash is sufficient to fund operations for at least one year from filing, "raising substantial doubt" about going concern; a May 15, 2026 release had framed cash plus recent financing as covering operations only into the third quarter of 2026. During the quarter, Moleculin raised about $8.3 million through a warrant inducement, exercising Series E and F warrants at $3.90 per share for new five-year Series H warrants covering up to 6.37 million shares. Shares outstanding rose from 3.2 million at year-end 2025 to 5.3 million at quarter-end, and to 5,336,350 by May 7, 2026.
About 10.0 million potentially dilutive shares were excluded from diluted loss per share, nearly double the outstanding count. This follows a 1-for-25 reverse split, effective December 1, 2025, cutting shares outstanding from about 51.6 million to about 2.07 million, partly to cure a Nasdaq bid-price deficiency. Moleculin had also fallen out of compliance with Nasdaq's $2.5 million equity rule from May 2025 and appealed a November 2025 delisting determination; Nasdaq confirmed the bid-price fix in December 2025 and the equity-rule fix in January 2026, cancelling the hearing.
Where Annamycin Could Go From Here
The timeline calls for completing Part A and unblinding in the third quarter of 2026, starting Part B in the second half of 2026, beginning third-line and pediatric AML studies in 2027, ending Part B recruitment in 2028, and beginning a rolling NDA submission in 2028 targeting accelerated approval on the CR endpoint. The company also cites a Cleveland Clinic-reviewed cardiac-safety analysis across roughly 90 subjects at ASCO in May 2026 showing no significant cardiotoxicity, and a June 2026 survey describing strong prescribing intent if approved. Every date assumes continued funding of a multi-year trial.
Material Risks Facing Moleculin Biotech
The primary risk is binary clinical outcome risk: unblinded 45-patient data lack statistical significance and may not hold in the larger population. Financing risk compounds this, given going-concern doubt and a track record of dilutive warrant transactions. Listing risk persists too; despite regained compliance, prior deficiencies plus a large warrant overhang with anti-dilution features could resurface. Cross-trial comparisons to historical benchmarks are also limited by differing treatment-cycle protocols.
Outlook
In an upside case, Part A completes on schedule, the CR and CRc advantage persists into Part B, and Moleculin funds itself without excessive dilution. In a base case, data track guidance but financing needs recur roughly every one to two quarters, keeping share-count growth persistent. In a downside case, the interim trend narrows or reverses, or financing becomes harder to secure, renewing listing and going-concern pressure.
Conclusion
Moleculin Biotech (MBRX) has produced an encouraging, company-reported interim signal for Annamycin in relapsed or refractory AML, but the June 30, 2026 MIRACLE data remain a small, unblinded, statistically inconclusive subset rather than confirmed efficacy. Investors must also weigh going-concern doubt, a recent 1-for-25 reverse split, a recent Nasdaq compliance episode, and a dilutive warrant structure that could reshape the share count before MIRACLE's fully powered results arrive.
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...